UNSPSC 51314200: Antihistamine or H1 blocker tropanes

This classification denotes antihistaminea or H1 blockers based on n-methyl-8-azabicyclo[3.2.1]octanes best known for the ones found in plants, sometimes called azabicyclo(3.2.1)octanes, and from whence many alkaloids come.

UNSPSC 51314200 Antihistamine or H1 blocker tropanes is a Class code, but the recent state and local opportunities tagged under it do not align with its nominal pharmaceutical scope. The three most recent solicitations—Seminole County's procurement of Naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescriptions, and MMCAP's generic multi-source pharmaceuticals and OTC products—represent broader pharmacy and medical supply sourcing rather than antihistamine-specific procurement. State and local governments buying under this code are acquiring pharmaceutical products through competitive bidding (IFB), information-gathering (RFI), and cooperative purchasing vehicles (MMCAP), with delivery, compliance (E-Verify, cGMP, DSCSA), insurance, and pricing transparency as common contract requirements. Issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). The code shows little recent activity specifically tied to antihistamines or H1 blockers as a distinct product class.

Activity is concentrated in Florida and Texas, with MMCAP's regional reach spanning Minnesota, Oregon, and other participating jurisdictions. Seminole County issued IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to Sanford, Florida; Texas HHS posted RFI HHS0017013 (April 3, 2026) to explore direct-to-manufacturer pharmacy relationships; and MMCAP released RFP S1070000015802 (posted January 20, 2026, proposals due March 26, 2026) for generic pharmaceuticals and OTC products through three authorized wholesalers, with the contract effective July 1, 2026. Vendors pursuing this code should note that recent procurement emphasizes cooperative purchasing models, multi-state reach, and direct manufacturer relationships rather than single-jurisdiction or product-line buys.